Positive phase III data for fezolinetant in nonhormonal treatment of vasomotor symptoms in postmenopausal women
The BRIGHT SKY phase III trials (n=1,028) demonstrated significant reductions from baseline in frequency and severity of moderate to severe vasomotor symptoms with fezolinetant, an oral neurokinin-3 receptor antagonist, versus placebo.
Source:
Biospace Inc.